Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents

Area of Science:

• Molecular Biology
• Hematology
• Cancer Research

Background:

• PU.1 (Purine-rich DNA binding, SPI1) is a critical transcription factor for hematopoiesis.
• PU.1 expression is regulated by transcriptional enhancers, DNA methylation, epigenetic factors, and microRNA-155 (miR-155).
• Myeloblastosis oncogene (MYB) influences progenitor maturation and PU.1 regulation.

Purpose of the Study:

• To investigate the combined effect of DNA methylation inhibitors, MYB inhibitors, and anti-miR-155 on PU.1 levels in acute myeloid leukemia (AML) cells.
• To determine if a combinatorial approach can achieve sustained PU.1 reactivation and induce leukemic differentiation.

Main Methods:

• Treatment of AML cells with 5-Azacytidine (DNA methylation inhibitor), Celastrol (MYB inhibitor), and AM155 (anti-miR-155).
• Assessment of PU.1 levels at both RNA and protein expression.
• Evaluation of the impact on myeloid transcriptional programs, cell survival, and proliferation.

Main Results:

• Combinatorial treatment led to PU.1 overproduction.
• Sustained PU.1 derepression at the protein level was achieved only with the triple combination.
• Increased PU.1 stimulated myeloid programs, inhibited cell survival and proliferation, resulting in partial leukemic differentiation.

Conclusions:

• A combined therapeutic strategy targeting DNA methylation, MYB, and miR-155 can effectively restore PU.1 levels in AML.
• Sustained PU.1 reactivation drives myeloid differentiation and exhibits anti-leukemic effects.
• This approach holds potential for treating acute myeloid leukemia by inducing differentiation.